摘要
目的:对药物经济学研究在新药研发过程中的介入时机进行分析。方法:构建新药Ⅰ~Ⅲ期临床试验阶段是否平行开展药物经济学研究决策模型,计算不同决策所产生的净收益,推导出在新药研发过程中开展药物经济学研究的约束条件。结果与结论:药物经济学研究也是一项经济行为,研发主体应根据其产生的经济结果进行决策。静态决策简单方便,但未考虑资金的时间价值,只能提供粗略的决策信息,研发主体应尽量采用动态决策的方法。为了减少决策的风险,还应对分析结果进行不确定性分析。
Objective:To analyze the right time to do pharmacoeconomic research at the drug research and development(R&D)phase.Methods:The making decision model was developed to answer whether the pharmacoeconomic research should be implement-ed at the Ⅰ~Ⅲ clinical trial phase. The net profit of different decisions was calculated to elicit the constraint conditions of implement-ing pharmacoeconomic research at the drug R&D phase.Results & Conclusion:Cost-benefit should also be considered to do pharma-coeconomic research, and the decision should be made based on the economic results. The static decision was easy and convenient,but excluded the time value of money and provided the rough information. Therefore, dynamic decision should be applied for researchsubjects. It should perform uncertainty analysis according to analysis results so as to reduce the risk of decision.
出处
《中国卫生经济》
北大核心
2015年第3期29-32,共4页
Chinese Health Economics
基金
国家自然科学基金项目(71463007/G0308)
贵州省科技厅社会攻关项目(黔科合SY字[2013]3068)
贵州省教育厅高校人文社会科学研究项目(黔教社发[2013]419)
贵阳医学院院基金项目([2013]05)
关键词
药物经济学
新药研发
临床试验
净收益
pharmacoeconomics
drug research and development
clinical trial
net profit
